LIKMEZ
Growthmetronidazole oral
NDAORALSUSPENSION
Approved
Sep 2023
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
4/8 — Partial
LIKMEZ (metronidazole oral) is 12. First approved in 2023.
Drug data last refreshed 15h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LIKMEZ is an oral nitroimidazole antimicrobial suspension containing metronidazole, approved in September 2023. It is a bactericidal agent that achieves therapeutic concentrations across multiple body compartments including cerebrospinal fluid and abscess sites. The drug is indicated for infections caused by susceptible anaerobic organisms and protozoa.
Growth13.3 years to LOE
Early-stage oral suspension in growth phase with 13+ years of patent protection; brand team likely building market awareness and establishing formulary relationships.
Mechanism of Action
12.1 Mechanism of Action Metronidazole is a nitroimidazole antimicrobial drug [ see ] . 12.3 Pharmacokinetics Metronidazole pharmacokinetics are similar for both oral and intravenous dosage forms. The C max is dose proportional between 250 mg, 500 mg, and 2,000 mg for metronidazole oral tablets,…
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.